Impact of subcutaneous allergoid AIT on patients with allergic rhinitis and/or asthma: A retrospective real-life, long-term cohort analysis

Abstract

Data on real-world outcomes of subcutaneous immunotherapy (SCIT) are scarce. To evaluate the effectiveness of SCIT with grass, tree or house dust mite allergoid preparations in the treatment of allergic rhinitis or asthma, we analyzed data on prescriptions of symptomatic medication in the relevant patient population.

The analyses were conducted with IMS LRx® (IQVIA, Frankfurt, Germany). For each allergen, we compared two groups of allergic patients: one group treated for at least 2 years with an allergoid SCIT, the control group received symptomatic medication only. We analyzed data over 9 years. The impact of SCIT was assessed by comparing the number of symptomatic prescriptions for allergic rhinitis or asthma between the SCIT group and the control group. The analysis was structured as a comparison between a pre-index period (at least 18 months before SCIT) and a follow up period (covering at least 2 years following SCIT) with a time adjustment for the latter period.

Considering the symptoms of allergic rhinitis in the follow-up period, the SCIT group had significantly less prescriptions of symptomatic medication in the follow up period compared to control group (house dust mite 59.7%, grass 64.8%, tree 56.0%). The number of symptomatic asthma prescriptions in the full analysis period was significantly lower in the SCIT group than in the control group (house dust mite 10.8%, grass 14.0%, tree 9.3%).

This real-world analysis of prescription data in allergic patients shows that SCIT with allergoid preparations reduced number of prescriptions of symptomatic allergic rhinitis and asthma medication, compared to control patients.